Artwork
iconShare
 
Manage episode 473915815 series 2838329
Content provided by VJHemOnc. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by VJHemOnc or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Newly diagnosed acute myeloid leukemia (AML) is traditionally treated with intensive chemotherapy for eligible patients, but ongoing research is exploring the addition of targeted agents. This podcast focuses on approaches being explored to optimize induction therapy in AML, featuring experts Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Curtis Lachowiez, MD, Oregon Health & Science University, Portland, OR, Ioannis Mantzaris, MD, Montefiore Medical Center/Albert Einstein College of Medicine, New York City, NY, Selina Luger, MD, FRCPC, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA, Harry Erba, MD, PhD, Duke University, Durham, NC, Fabio Guolo, MD, University of Genoa, Genoa, Italy, and David Sallman, MD, Moffitt Cancer Center, Tampa, FL.

The experts discuss key trials in this space, including venetoclax combined with intensive induction chemotherapy, a Phase II study comparing midostaurin with gilteritinib in FLT3-mutated AML (NCT03836209), and the combination of ziftomenib with intensive chemotherapy. They also examine the role of CPX-351 in induction therapy and its potential combination with gemtuzumab ozogamicin.

  continue reading

200 episodes